Variant Bio Strengthens Leadership with Dr. Craig T. Basson as CMO to Enhance Genomic Research Variant Bio has appointed Dr. Craig T. Basson as Chief Medical Officer, aiming to leverage his expertise in genomics to advance clinical programs significantly.

Variant Bio Strengthens Leadership with Dr. Craig T. Basson as CMO to Enhance Genomic Research #USA #Seattle #Genomics #Variant_Bio #Craig_Basson

Variant Bio Partners with Boehringer Ingelheim to Tackle Kidney Disease Through AI Innovation Variant Bio has established a significant partnership with Boehringer Ingelheim to facilitate the discovery of new targets for treating kidney disease, utilizing cutting-edge AI technology.

Variant Bio Partners with Boehringer Ingelheim to Tackle Kidney Disease Through AI Innovation #USA #Seattle #Boehringer_Ingelheim #kidney_disease #Variant_Bio

Variant Bio Unveils Inference: A Revolutionary AI Genomic Drug Discovery Platform Variant Bio has launched Inference, the groundbreaking AI-powered genomic drug discovery platform, enhancing pharmaceutical research capabilities globally.

Variant Bio Unveils Inference: A Revolutionary AI Genomic Drug Discovery Platform #USA #Seattle #Drug_Discovery #Variant_Bio #AI_Genomics

Variant Bio and Novo Nordisk Join Forces for Groundbreaking Metabolic Disease Research Variant Bio announces a multi-year partnership with Novo Nordisk to explore novel targets for treating metabolic diseases, enhancing global health opportunities.

Variant Bio and Novo Nordisk Join Forces for Groundbreaking Metabolic Disease Research #USA #Seattle #Novo_Nordisk #Variant_Bio #metabolic_disease